Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternating Nintedanib and Afatinib in Advanced Colorectal Cancer
NCT00801294Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2006
- Primary completion
- Nov 2007
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nintedanib, afatinib in metastatic colorectal cancer (mCRC), sponsored by Boehringer Ingelheim. Started Jul 2006; status: completed.
02
Drugs
nintedanibafatinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00801294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00801294.